23 May 2023: Original Paper
Safety and Efficacy of 4 mg·kg Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial
Jiancheng Tang 12ABCDEFG , Rongzhi He 2ABCEF , Lei Zhang 3ABD , Shiyuan Xu 1ABCDEFG*DOI: 10.12659/AOT.940211
Ann Transplant 2023; 28:e940211
Table 2 The changes of Scr, CCr, AMS, Glu, MAP and HR of two groups patients.
| T0 | T1 | T2 | T3 | T4 | T5 | T6 | ||
|---|---|---|---|---|---|---|---|---|
| Group S | Scr | 918±176 | 778±174 | 431±135 | 331±116 | 234±97 | 203±73 | 176±57 |
| CCr | 14.8±3.5 | 33.6±2.1 | 29.1±3.3 | 44.6±3.2 | 60.8±3.0 | 64.2±2.9 | 67.9±2.8 | |
| Glu** | 5.60±1.1 | 9.30±0.69** | 7.93±0.7 | 6.78±0.3 | 6.48±0.6 | 6.04±0.5 | 6.41±0.4 | |
| AMS | 152±18 | 112±14 | 99±12 | 89±11 | 77±13 | 67±10 | 75±11 | |
| MAP** | 90±14 | 95±17** | 82±16 | 76±10 | 86±13 | 86±15 | 79±12 | |
| HR** | 80±8 | 93±7** | 71±9 | 71±11 | 67±7 | 76±8 | 73±5 | |
| Group N | Scr | 996±162 | 815±142 | 422±104 | 293±83 | 220±85 | 218±78 | 217±86 |
| CCr | 15.3±2.4 | 28.1±2.4 | 28.0±1.9 | 44.3±2.9 | 61.5±2.7 | 64.3±2.8 | 66.1±2.5 | |
| Glu** | 5.15±0.61 | 6.10±0.53** | 7.62±0.6 | 6.75±0.6 | 6.26±0.6 | 5.59±0.3 | 6.19±0.5 | |
| AMS | 149±16 | 120±13 | 92±14 | 93±13 | 82±11 | 75±12 | 80±14 | |
| MAP** | 88±12 | 77±14** | 81±13 | 73±15 | 83±12 | 80±14 | 77±11 | |
| HR** | 83±8 | 70±8** | 66±8 | 73±9 | 64±7 | 73±5 | 69±8 | |
| Values are expressed as mean±(standard deviation, SD). #, *, ## There was no difference in Scr, CCr and AMS in both groups at the same timepoints after our intervention (P>0.05); ** Glu, MAP, and HR at T1 in group S were higher than that in group N after our intervention (P Scr – serum creatinine; CCr – creatinine clearance rate; Glu – plasma glucose concentration; AMS – serum amylase; MAP – mean arterial pressure; – HR – heart rate; S – sugammadex; N – neostigmine; T0 the start of surgery, T1 (8 hours), T2 (12 hours), T3 (36 hours), T4 (60 hours), T5 (84 hours), T6 (108 hours) after the surgery. | ||||||||